{"id":"https://openalex.org/W1596459151","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p4-15-07","title":"Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio\u22652.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy","display_name":"Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio\u22652.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy","publication_year":2015,"publication_date":"2015-05-01","ids":{"openalex":"https://openalex.org/W1596459151","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p4-15-07","mag":"1596459151"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs14-p4-15-07","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p4-15-07","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs14-p4-15-07","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056478400","display_name":"Chad Livasy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chad A Livasy","raw_affiliation_strings":["1Levine Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Levine Cancer Institute","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014146314","display_name":"Kimberly Limentani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly Limentani","raw_affiliation_strings":["2Cleveland Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Cleveland Clinic","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065682470","display_name":"Benjamin C. Calhoun","orcid":"https://orcid.org/0000-0001-6505-5430","observed_orcids":["https://orcid.org/0000-0001-6505-5430"]},"institutions":[{"id":"https://openalex.org/I2799360765","display_name":"Thomas Jefferson University Hospital","ror":"https://ror.org/04zhhva53","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799360765","https://openalex.org/I4210114575"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin C Calhoun","raw_affiliation_strings":["3Thomas Jefferson University Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Thomas Jefferson University Hospital","institution_ids":["https://openalex.org/I2799360765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048571413","display_name":"Steven A. Limentani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Limentani","raw_affiliation_strings":["4Levine Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Levine Cancer Institute","institution_ids":["https://openalex.org/I4210100342"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"75","issue":"9_Supplement","first_page":"P4","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9480000138282776},{"id":"https://openalex.org/keywords/her2-cep17-ratio","display_name":"HER2/CEP17 ratio","score":0.9169999957084656},{"id":"https://openalex.org/keywords/cep17","display_name":"CEP17","score":0.718999981880188},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy-response","display_name":"neoadjuvant chemotherapy response","score":0.8740000128746033},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9200000166893005},{"id":"https://openalex.org/keywords/residual-cancer-burden","display_name":"residual cancer burden","score":0.8199999928474426},{"id":"https://openalex.org/keywords/clinicopathological-features","display_name":"clinicopathological features","score":0.7329999804496765},{"id":"https://openalex.org/keywords/hormone-receptor-status","display_name":"hormone receptor status","score":0.6499999761581421},{"id":"https://openalex.org/keywords/her2-expression","display_name":"HER2 expression","score":0.4099999964237213},{"id":"https://openalex.org/keywords/invasive-ductal-carcinoma","display_name":"invasive ductal carcinoma","score":0.6610000133514404}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6591538786888123},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.6576054096221924},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.6522701382637024},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6427003145217896},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5853986144065857},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5301768779754639},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.44562190771102905},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42716076970100403},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4157072901725769},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.3997027277946472},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2849646806716919},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs14-p4-15-07","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p4-15-07","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs14-p4-15-07","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2013365705","https://openalex.org/W2890548997","https://openalex.org/W2792984923","https://openalex.org/W2886899602","https://openalex.org/W4313248233","https://openalex.org/W4287879581","https://openalex.org/W2224149066","https://openalex.org/W6939546104","https://openalex.org/W2594401478","https://openalex.org/W2585180563"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"ASCO/CAP":[2,408],"guidelines":[3,409],"for":[4,34,109,189,371],"the":[5,35,44,58,82,99,192,197,210,284,377,383,404,456],"determination":[6],"of":[7,39,43,47,60,64,70,183,196,263,272,379,407,455],"HER2":[8,24,48,91,102,119,131,140,229,286,338,352,380,412,426,436,445],"amplification":[9],"have":[10,55],"recently":[11],"been":[12],"revised":[13],"in":[14,67,87,191,357],"an":[15],"attempt":[16],"to":[17,107,276,397,410,449],"clarify":[18],"which":[19],"patients":[20,163,199,256,265,373],"will":[21],"benefit":[22],"from":[23,135,138],"directed":[25],"therapy.":[26],"Patients":[27],"with":[28,90,124,209,344,433,444],"HER2/CEP17":[29,83,113,125,346],"ratios":[30],"\u22652.0":[31,115,127,348],"were":[32,133,160,200,204,374],"eligible":[33],"first":[36],"generation":[37],"trials":[38],"adjuvant":[40],"trastuzumab":[41,269],"regardless":[42],"average":[45,117,129,350,434],"number":[46,76],"signals/cell.":[49,120],"Array":[50],"CGH":[51],"and":[52,78,85,105,116,128,144,157,176,224,241,349,360,401,437,447],"FISH":[53,185,339],"studies":[54],"since":[56],"demonstrated":[57,232,393],"presence":[59],"complex":[61],"segmental":[62],"aneusomy":[63],"chromosome":[65],"17":[66],"a":[68,112,345,394],"subset":[69],"breast":[71],"tumors.":[72],"These":[73],"focal":[74],"copy":[75],"gains":[77],"losses":[79],"can":[80],"skew":[81],"ratio":[84,114,126,347],"result":[86],"discordant":[88],"results":[89],"immunohistochemistry":[92,446],"(IHC).":[93],"There":[94],"is":[95],"limited":[96],"data":[97,389],"on":[98,146],"clinicopathologic":[100],"features,":[101,442],"protein":[103,230],"expression":[104],"response":[106,167,396,448],"therapy":[108,274],"tumors":[110,203,248,392],"showing":[111],"<4.0":[118,351,435],"Methods:":[121],"All":[122,202],"cases":[123,186],"<4":[130],"signals/cell":[132,353],"identified":[134,148],"our":[136],"database":[137],"2009-2013.":[139],"IHC":[141],"was":[142,168],"performed":[143],"scored":[145],"all":[147],"cases.":[149],"Tumor":[150],"grade,":[151],"histologic":[152],"subtype,":[153],"hormone":[154],"receptor":[155,221,226],"status":[156,159,287,381],"menopausal":[158],"recorded.":[161],"For":[162],"receiving":[164],"neoadjuvant":[165,258,398,450],"chemotherapy,":[166],"measured":[169],"using":[170],"residual":[171],"cancer":[172],"burden":[173],"(RCB)":[174],"class":[175],"yAJCC":[177],"pathologic":[178],"stage.":[179],"Results:":[180],"70":[181,198],"(1.5%)":[182],"4659":[184],"met":[187],"criteria":[188],"inclusion":[190],"study.":[193],"22":[194],"(31%)":[195],"premenopausal.":[201],"ductal":[205],"(no":[206],"special":[207],"type)":[208],"following":[211],"features":[212],"features:":[213],"low-grade":[214],"14%,":[215],"intermediate-grade":[216],"40%,":[217],"high-grade":[218],"45%,":[219],"estrogen":[220],"positive":[222,227,244,340,427],"79%":[223],"progesterone":[225],"65%.":[228],"evaluation":[231],"52":[233],"(74%)":[234],"negative":[235],"(0-1+),":[236],"16":[237],"(23%)":[238],"equivocal":[239],"(2+)":[240],"2":[242,302],"(3%)":[243],"(3+)":[245],"results.":[246],"Most":[247],"(83%)":[249],"showed":[250],"1+":[251,363],"or":[252,281,364],"2+":[253,365],"staining.":[254],"12":[255,332],"received":[257],"chemotherapy":[259,290,400,451],"(see":[260],"table).":[261],"Six":[262],"these":[264,372,391],"did":[266],"not":[267],"receive":[268],"as":[270],"part":[271],"their":[273],"due":[275],"congestive":[277],"heart":[278,335],"failure":[279,336],"(n=1)":[280],"uncertainty":[282,378],"about":[283],"patient's":[285],"(n=5).":[288],"Neoadjuvant":[289],"patient":[291],"summaryPatient":[292],"#":[293],"(regimen)RatioHER2":[294],"copy#CEP17":[295],"copy#HER2":[296],"IHCER/PRyAJCCRCB":[297],"classPatient":[298],"1":[299],"(AC+TH)2.23.91.81++/+ypT0":[300],"N0(i+)1Patient":[301],"(TCH)2.23.81.71++/-ypT0":[303],"N00Patient":[304,307,316,319,325],"3":[305],"(TCH)2.23.81.72++/+ypTis":[306],"4":[308],"(AC+TH)2.33.01.30+/+ypT2":[309],"N2a2Patient":[310],"5":[311],"(TCH)2.23.71.71+-/-ypT1c":[312],"N01Patient":[313],"6":[314],"(TCH)2.23.91.82+-/-ypTis":[315],"7":[317],"(TC)*2.03.41.70-/-ypT0":[318],"8":[320],"(AC+T)2.23.61.71++/-ypT1c":[321],"N02Patient":[322],"9":[323],"(TC)2.13.91.91+-/-ypT0":[324],"10":[326],"(AC)2.53.41.41++/+ypT1b":[327],"N1a2Patient":[328],"11":[329],"(TAC)2.43.61.52+-/-ypT3":[330],"N1mi2Patient":[331],"(AC)2.03.31.61+-/-ypT1c":[333],"N1a2*Congestive":[334],"Conclusions:":[337],"invasive":[341,430],"mammary":[342,431],"carcinomas":[343,432],"are":[354],"rare":[355],"(1.5%":[356],"this":[358,387],"study)":[359],"frequently":[361],"show":[362],"staining":[366],"by":[367,376],"IHC.":[368],"Treatment":[369],"decisions":[370],"impacted":[375],"under":[382],"previous":[384],"guidelines.":[385],"In":[386],"small":[388],"set,":[390],"good":[395],"trastuzumab-based":[399],"further":[402],"support":[403],"recent":[405],"modifications":[406],"determine":[411],"amplification.":[413],"Citation":[414],"Format:":[415],"Chad":[416],"A":[417],"Livasy,":[418],"Kimberly":[419],"Limentani,":[420],"Benjamin":[421],"C":[422],"Calhoun,":[423],"Steven":[424],"Limentani.":[425],"(HER2/CEP17":[428],"ratio\u22652.0)":[429],"<2.0":[438],"CEP17":[439],"signals/cell:":[440],"Clinicopathologic":[441],"correlation":[443],"[abstract].":[452],"In:":[453],"Proceedings":[454],"Thirty-Seventh":[457],"Annual":[458],"CTRC-AACR":[459],"San":[460,468],"Antonio":[461],"Breast":[462],"Cancer":[463,474],"Symposium:":[464],"2014":[465],"Dec":[466],"9-13;":[467],"Antonio,":[469],"TX.":[470],"Philadelphia":[471],"(PA):":[472],"AACR;":[473],"Res":[475],"2015;75(9":[476],"Suppl):Abstract":[477],"nr":[478],"P4-15-07.":[479]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}